Mario Balsa, Medical Oncology Resident at Catalan Institute of Oncology, shared a post on X about a paper by Vito Amodio et al. published in Cancer Cell:
“New in Cancer Cell: adaptive plasticity drives early escape from targeted therapy!
- Dual EGFR–KRAS inhibition → reversible Paneth-like state via SMAD1–FGFR3
- Lineage switching sustains MAPK signaling before genetic resistance kicks in
Targeted therapy, adaptive biology.”
Title: Adaptive plasticity in targeted therapy
Authors: Vito Amodio, Giorgio Patelli, Alberto Bardelli
You can read the Full Article in Cancer Cell.
More posts featuring Mario Balsa.
